Physician profile
Bahige Asaker
NPI 1104927102
$14,385.13
in general payments reported to CMS, 2019-2025
59 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,651 · 2020: $935 · 2021: $2,400 · 2022: $2,257 · 2023: $1,918 · 2024: $2,084 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,141.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,549.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,276.35 | 2019-2025 | Vraylar |
| Pfizer INC. | $1,126.48 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $862.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $752.16 | 2019-2025 | |
| Lilly USA, LLC | $716.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $623.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.80 | 2019-2025 | Jardiance, Jascayd |
| Janssen Pharmaceuticals, INC | $463.32 | 2019-2021 | |
| Mylan Specialty L.P. | $450.87 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $369.91 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Allergan, INC. | $339.89 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $333.34 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $332.70 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $304.60 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $282.51 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $249.57 | 2019-2023 | Camzyos, Eliquis |
| Lundbeck LLC | $239.15 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $233.25 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $217.61 | 2024-2025 | Voquezna |
| Abbott Laboratories | $217.16 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $210.29 | 2023-2024 | Sunosi |
| Eisai INC. | $204.79 | 2020-2025 | |
| Medtronic, INC. | $201.63 | 2023-2025 | Minimed 780g, Intellis Adaptivestim, Inpen Smart Insulin Delivery System |
| Kowa Pharmaceuticals America, INC. | $185.77 | 2020-2025 | Zoryve |
| Exact Sciences Corporation | $172.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $165.19 | 2019-2022 | |
| Shield Therapeutics INC | $138.26 | 2023-2024 | Accrufer |
| Gilead Sciences, INC. | $137.11 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.88 | 2022-2025 | Xifaxan |
| Ani Pharmaceuticals, INC. | $115.49 | 2023-2024 | Purified Cortrophin Gel |
| Avanir Pharmaceuticals, INC. | $107.76 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $106.14 | 2021-2022 | |
| Daiichi Sankyo INC. | $96.74 | 2022-2023 | Injectafer |
| Amgen INC. | $95.85 | 2021-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $92.71 | 2022 | |
| Esperion Therapeutics, INC. | $84.22 | 2020-2021 | |
| Verona Pharma, INC. | $79.03 | 2025 | Ohtuvayre |
| Amneal Pharmaceuticals LLC | $74.34 | 2022-2025 | Unithroid |
| Indivior INC. | $59.13 | 2023 | Perseris |
| Scilex Pharmaceuticals INC. | $47.85 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.42 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $44.34 | 2023-2025 | Givlaari, Onpattro |
| Sanofi Pasteur INC. | $41.80 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $34.02 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $29.29 | 2019-2020 | |
| Dexcom, INC. | $27.08 | 2025 | Dexcom G6 Transmitter |
| Covis Pharma Gmbh | $25.81 | 2022 | |
| Astellas Pharma US INC | $23.44 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $22.38 | 2023 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $20.66 | 2019 | |
| Seqirus USA INC | $20.42 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.45 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.99 | 2021 | |
| Cequr Corporation | $18.85 | 2025 | Cequr Simplicity |
| Vanda Pharmaceuticals INC. | $18.32 | 2025 | Fanapt |
| Smith+Nephew, INC. | $17.84 | 2020 | |
| Bausch Health US, LLC | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahige Asaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.